Bellevue Group Ag Macrogenics Inc Transaction History
Bellevue Group Ag
- $5.98 Billion
- Q2 2024
A detailed history of Bellevue Group Ag transactions in Macrogenics Inc stock. As of the latest transaction made, Bellevue Group Ag holds 9,942,313 shares of MGNX stock, worth $31.7 Million. This represents 0.71% of its overall portfolio holdings.
Number of Shares
9,942,313
Previous 9,965,862
0.24%
Holding current value
$31.7 Million
Previous $147 Million
71.2%
% of portfolio
0.71%
Previous 2.3%
Shares
26 transactions
Others Institutions Holding MGNX
# of Institutions
154Shares Held
60.6MCall Options Held
218KPut Options Held
259K-
Armistice Capital, LLC New York, NY6MShares$19.1 Million0.33% of portfolio
-
Black Rock Inc. New York, NY5.4MShares$17.2 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.14MShares$13.2 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny3.31MShares$10.6 Million0.01% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA3.01MShares$9.6 Million0.75% of portfolio
About MACROGENICS INC
- Ticker MGNX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 61,458,800
- Market Cap $196M
- Description
- MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients ...